Media Center

News Releases

KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss
February 9, 2015

Westlake Village, Calif., February 10, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that it has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and…

KYTHERA Biopharmaceuticals Submits Drug Application in Australia for Novel Submental Contouring Injectable Drug ATX-101
February 4, 2015

Submission marks company’s fourth ATX-101 global regulatory filing Westlake Village, Calif., February 4, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced its submission to Australia’s Therapeutic Goods Administration (TGA) for ATX-101 (deoxycholic acid), its potential first-in-class treatment for improving submental fullness associated with submental (under the chin) fat. This milestone in KYTHERA’s ATX-101 global…

KYTHERA Biopharmaceuticals To Present at the 2015 Leerink Global Healthcare Conference
February 4, 2015

Westlake Village, Calif., February 4, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference. Event:        2015 Leerink Global Healthcare Conference Date:         Wednesday, February 11, 2015 Time:        10:40 a.m. ET A live webcast will be…

KYTHERA Biopharmaceuticals Announces Date of FDA Advisory Committee Review of ATX-101 for the Treatment of Submental Fullness
January 23, 2015

Westlake Village, Calif., January 23, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced the Dermatology and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review KYTHERA’s New Drug Application (NDA) for ATX-101 (deoxycholic acid) for improvement in the appearance of moderate to severe submental fullness in a…

KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
January 5, 2015

Former Onyx CEO Brings Additional Company Building Experience to KYTHERA Board   Westlake Village, Calif., January 5, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that it has named Hollings C. Renton to its Board of Directors. Mr. Renton brings extensive biotechnology leadership experience to KYTHERA. He has over 25 years of experience building successful biotechnology…

KYTHERA Biopharmaceuticals To Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 5, 2015

Westlake Village, Calif., January 5, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. Event:        33rd Annual J.P. Morgan Healthcare Conference Date:         Monday, January 12, 2015 Time:        11:00 a.m. PT…

KYTHERA Biopharmaceuticals To Present at the Goldman Sachs US Emerging / SMID Cap Growth Conference
November 14, 2014

Westlake Village, Calif., November 14, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York. Event:        Goldman Sachs US Emerging / SMID Cap Growth Conference Date:          Thursday, November 20, 2014 Time: …

KYTHERA Biopharmaceuticals Releases Third Quarter 2014 Operating Results
November 10, 2014

Westlake Village, Calif., November 10, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its third quarter 2014 and provided an update on recent accomplishments. “We’ve demonstrated good progress in advancing our ATX-101 program. Of note, we continue to increase our medical affairs efforts as well as our preparations for potential commercialization,…

KYTHERA Biopharmaceuticals To Release Third Quarter 2014 Operating Results
November 3, 2014

Westlake Village, Calif., November 3, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it will release its third quarter 2014 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, November 10, 2014. Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or…

KYTHERA Biopharmaceuticals Submits New Drug Submission to Health Canada for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat
August 11, 2014

Westlake Village, Calif., Aug. 11, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company’s investigational drug, ATX-101 (deoxycholic acid), as an injectable treatment for the reduction of submental fat. The NDS is supported by results from two pivotal Phase III trials,…